Sol-Gel Technologies Ltd
SLGL
Company Profile
Business description
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Contact
7 Golda Meir Street
Weizmann Science Park
Ness Ziona7403650
ISRT: +972 89313433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
34
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
stocks
ASX coal miners will benefit from higher prices
Middle East conflict pushes coal prices higher.
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
We think Nvidia stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,690.70 | 21.10 | -0.24% |
| CAC 40 | 7,842.41 | 127.47 | -1.60% |
| DAX 40 | 22,947.05 | 555.20 | -2.36% |
| Dow JONES (US) | 45,935.32 | 289.83 | -0.63% |
| FTSE 100 | 10,067.89 | 237.40 | -2.30% |
| HKSE | 25,500.58 | 524.84 | -2.02% |
| NASDAQ | 22,024.40 | 128.02 | -0.58% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 13,051.61 | 263.99 | -1.98% |
| S&P 500 | 6,593.88 | 30.82 | -0.47% |
| S&P/ASX 200 | 8,497.80 | 7.60 | -0.09% |
| SSE Composite Index | 4,006.55 | 56.43 | -1.39% |